News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Subscribe To Our Newsletter & Stay Updated
